Emergent acquiring vaccine company PaxVax

Biodefense company Emergent BioSolutions Inc. (NYSE:EBS) will acquire vaccine company PaxVax Inc. (Redwood City, Calif.) for $270 million in cash.

Emergent will gain Vivotif and Vaxchora, which PaxVax markets to prevent typhoid fever and cholera, respectively. Vivotif is an oral typhoid vaccine that contains live-attenuated cells of the bacteria that cause typhoid fever, and Vaxchora is a live-attenuated vaccine against Vibrio cholerae delivered as a single oral liquid dose. PaxVax acquired Vivotif from Johnson & Johnson (NYSE:JNJ) in 2014...